Investigating infections in critically ill patients on continuous renal replacement therapy
The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial
This study looks at critically ill patients on a special kidney treatment to see how often they get new infections and what might cause them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Muenster Academic / other |
| Locations | 5 sites (Innsbruck and 4 other locations) |
| Trial ID | NCT05450185 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on critically ill patients undergoing continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). It aims to analyze the incidence and characteristics of new infections associated with CRRT, as well as the factors influencing these infections. The study is based on findings from a post-hoc analysis of the RICH trial, which suggested a link between filter lifespan and infection rates. By understanding these dynamics, the research seeks to improve patient outcomes in the ICU setting.
Who should consider this trial
Good fit: Ideal candidates include adult patients aged 18 and older who are critically ill with dialysis-dependent AKI and receiving CRRT.
Not a fit: Patients with chronic kidney disease, chronic dialysis dependency, or those with certain immunosuppressive conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for infections in critically ill patients receiving CRRT.
How similar studies have performed: While there have been studies on CRRT, this specific investigation into the relationship between filter lifespan and infection rates is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with dialysis-dependent AKI * Continuous renal replacement therapy (CRRT) * Written informed consent Exclusion Criteria: * Chronic kidney disease with estimated glomerular filtration rate (eGFR)\<30ml/min/1.73m2 * Chronic dialysis dependency * Kidney transplant * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Patients on immunosuppression * Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis) * Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
Where this trial is running
Innsbruck and 4 other locations
- Univ.-Klinik Innsbruck — Innsbruck, Austria (Recruiting)
- Universidade de São Paulo — São Paulo, Brazil (Recruiting)
- Universitätsklinikum Erlangen-Nürnberg, Abteilung für Nephrologie und Hypertensiologie — Erlangen, Germany (Recruiting)
- Kliniken Maria Hilf, Klinik für Anästhesiologie und Operative Intensivmedizin — Mönchengladbach, Germany (Recruiting)
- University Hospital Muenster — Münster, Germany (Recruiting)
Study contacts
- Principal investigator: Alexander Zarbock, MD — University Hospital Münster
- Study coordinator: Alexander Zarbock, MD
- Email: zarbock@uni-muenster.de
- Phone: +49-251-8347252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.